CONGESTIVE HEART FAILURE DRUGS MARKET ANALYSIS

Regional Analysis

Congestive Heart Failure Drugs Market Regional Analysis:-

North America is expected to hold dominant position in congestive heart failure drugs market due to new product launches and mergers and acquisitions. For instance, in 2015, Amgen Inc. a U.S.-based company acquired Dezima Pharma, a Netherlands based company to expand its cardiovascular drug portfolio by adding cholesterol lowering drug TA-8995 to its portfolio. TA-8995 is a cholesterol lowering drug. Moreover, Europe congestive heart failure drugs market is expected to witness significant growth due to launch of new drugs to treat chronic diseases, which prevent heart failures. For instance, Novartis AG launched a drug named Entresto in 2016, in UK. Entresto is used to treat heart failure with minimum ejection fraction (measurement of percentage of blood leaving heart each time it contracts), it is an angiotensin receptor-neprilysin inhibitor. Moreover, high prevalence of cardiovascular diseases in Asia Pacific is expected to support the growth of congestive heart failure drugs market in this region. According to a study conducted by All India Institute of Medical Science (AIIMS) and Indian Council of Medical Research (ICMR) in 2016, India’s younger population i.e. below 30 years of age are at a higher risk of developing cardiovascular diseases due to unhealthy lifestyle, alcohol consumption, and tobacco consumption,.